Aspera Biomedicines Successfully Launches Second ADAR1p150 Crystallization Experiment to the International Space Station Aboard SpaceX CRS-34
Second ADAR1p150 crystallization flight — Aspera’s 11th ISS mission overall — now operating in microgravity to advance development of an oral Rebecsinib formulation for clinical trials across advanced cancers
Aspera Biomedicines Inc., a biotechnology company developing first-in-class therapies targeting cancer stem cells, today announced that its second ADAR1p150 protein crystallization experiment has successfully launched aboard the SpaceX CRS-34 commercial resupply mission to the International Space Station (ISS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518560401/en/ This is a photo of Catriona Jamieson (left), Patrick Chang (middle-left), James La Clair (middle-right), and Karla Mack (right) preparing the second protein crystallization experiment for launch on CRS-34 using Redwire’s PIL-BOX system. Photo credit: Aspera Biomedicines
Following two weather-related launch scrubs earlier in the week, the Falcon 9 rocket lifted off at 6:05 PM EDT on Friday, May 15, from Cape Canaveral Space Force Station’s Space Launch Complex 40 in Florida. After an approximately 36-hour transit, the Dragon spacecraft carrying Aspera’s payload autonomously docked with the forward port of the station’s Harmony module at 6:37 AM EDT on Sunday, May 17 — slightly ahead of the originally scheduled 7:00 AM EDT target. The crystallization experiment is now operating in microgravity.
